Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/acn3.51342 http://scihub22266oqcxt.onion/10.1002/acn3.51342 33783140!8045943!33783140     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33783140&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Ann+Clin+Transl+Neurol 2021 ; 8 (4): 938-943 Nephropedia Template TP {{tp|p=33783140|t=2021. Multiple sclerosis, rituximab, and COVID-19 |pdf=|usr=}}{{33783140}} gab.com Text Multiple sclerosis, rituximab, and COVID-19 JO: Ann Clin Transl Neurol http://www.kidney.de/pget.php?&tw=1&pmid=33783140 #FOAvip We conducted a retrospective cohort study in Kaiser Permanente Southern California from 1 January 2020 to 30 September 2020. We found that rituximab-treated persons with multiple sclerosis (pwMS, n = 1895) were more likely be hospitalized (n = 8, 33.3%), but not die (n = 0) from COVID-19, compared to the 4.81 million non-MS population (5.8% and 1.4%, respectively). Time in months (adjusted OR = 0.32, 95% CI = 0.15-0.69, p = 0.0033) and receiving 1000 mg compared to lower doses at last infusion (adjusted OR = 6.28, 95% CI = 1.38-28.5, p = 0.0173) were independent predictors of COVID-19 severity. Rituximab-treated pwMS should be counseled to take extra precautions in the 5 months following each infusion. Using extended dosing intervals and lower doses could be considered. Twit Text FOAVip Multiple sclerosis, rituximab, and COVID-19 ????Ann Clin Transl Neurol http://www.kidney.de/pget.php?&tw=1&pmid=33783140 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33783140 #FOAvip English Wikipedia <ref>{{Cite pmid|33783140}}</ref> Multiple sclerosis, rituximab, and COVID-19 #MMPMID33783140 Langer-Gould A; Smith JB; Li BH Ann Clin Transl Neurol 2021[Apr]; 8 (4): 938-943 PMID33783140show ga We conducted a retrospective cohort study in Kaiser Permanente Southern California from 1 January 2020 to 30 September 2020. We found that rituximab-treated persons with multiple sclerosis (pwMS, n = 1895) were more likely be hospitalized (n = 8, 33.3%), but not die (n = 0) from COVID-19, compared to the 4.81 million non-MS population (5.8% and 1.4%, respectively). Time in months (adjusted OR = 0.32, 95% CI = 0.15-0.69, p = 0.0033) and receiving 1000 mg compared to lower doses at last infusion (adjusted OR = 6.28, 95% CI = 1.38-28.5, p = 0.0173) were independent predictors of COVID-19 severity. Rituximab-treated pwMS should be counseled to take extra precautions in the 5 months following each infusion. Using extended dosing intervals and lower doses could be considered. |Adult[MESH] |COVID-19/*epidemiology/therapy[MESH] |Cohort Studies[MESH] |Female[MESH] |Hospitalization/trends[MESH] |Humans[MESH] |Immunologic Factors/*administration & dosage[MESH] |Infusions, Intravenous[MESH] |Male[MESH] |Middle Aged[MESH] |Multiple Sclerosis/*drug therapy/*epidemiology[MESH] |Retrospective Studies[MESH]Multiple sclerosis, rituximab, and COVID-19 (epmc).pdf DeepDyve Pubget Overpricing